T. Rowe Price Associates’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.9B | Sell |
13,992,224
-918,281
| -6% | -$931M | 1.49% | 9 |
|
|
2025
Q4 | $16B | Buy |
14,910,505
+1,432,069
| +11% | +$1.37B | 1.73% | 9 |
|
|
2025
Q3 | $10.3B | Sell |
13,478,436
-3,366,669
| -20% | -$2.51B | 1.1% | 13 |
|
|
2025
Q2 | $13.1B | Sell |
16,845,105
-2,288,179
| -12% | -$1.78B | 1.49% | 10 |
|
|
2025
Q1 | $15.8B | Sell |
19,133,284
-1,730,684
| -8% | -$1.44B | 1.95% | 6 |
|
|
2024
Q4 | $16.1B | Sell |
20,863,968
-66,319
| -0.3% | -$54.9M | 1.86% | 7 |
|
|
2024
Q3 | $18.5B | Buy |
20,930,287
+278,551
| +1% | +$250M | 2.13% | 6 |
|
|
2024
Q2 | $18.7B | Buy |
20,651,736
+38,675
| +0.2% | +$30.9M | 2.24% | 6 |
|
|
2024
Q1 | $16B | Sell |
20,613,061
-1,213,514
| -6% | -$864M | 1.97% | 6 |
|
|
2023
Q4 | $12.7B | Sell |
21,826,575
-409,417
| -2% | -$239M | 1.71% | 9 |
|
|
2023
Q3 | $11.9B | Sell |
22,235,992
-1,924,967
| -8% | -$992M | 1.75% | 9 |
|
|
2023
Q2 | $11.3B | Buy |
24,160,959
+1,438,225
| +6% | +$603M | 1.58% | 9 |
|
|
2023
Q1 | $7.8B | Buy |
22,722,734
+53,744
| +0.2% | +$18.1M | 1.17% | 11 |
|
|
2022
Q4 | $8.29B | Sell |
22,668,990
-2,170,332
| -9% | -$770M | 1.33% | 10 |
|
|
2022
Q3 | $8.05B | Buy |
24,839,322
+4,412,664
| +22% | +$1.4B | 1.32% | 9 |
|
|
2022
Q2 | $6.62B | Sell |
20,426,658
-498,109
| -2% | -$150M | 0.84% | 17 |
|
|
2022
Q1 | $5.99B | Sell |
20,924,767
-4,259,691
| -17% | -$1.1B | 0.6% | 23 |
|
|
2021
Q4 | $6.96B | Sell |
25,184,458
-5,071,623
| -17% | -$1.29B | 0.63% | 23 |
|
|
2021
Q3 | $6.99B | Buy |
30,256,081
+3,516,865
| +13% | +$868M | 0.66% | 22 |
|
|
2021
Q2 | $6.14B | Buy |
26,739,216
+584,215
| +2% | +$117M | 0.57% | 28 |
|
|
2021
Q1 | $4.89B | Buy |
26,155,001
+14,060,388
| +116% | +$2.75B | 0.49% | 32 |
|
|
2020
Q4 | $2.04B | Buy |
12,094,613
+4,082,728
| +51% | +$610M | 0.21% | 108 |
|
|
2020
Q3 | $1.19B | Buy |
8,011,885
+1,656,667
| +26% | +$256M | 0.14% | 157 |
|
|
2020
Q2 | $1.04B | Buy |
6,355,218
+2,062,623
| +48% | +$317M | 0.13% | 163 |
|
|
2020
Q1 | $595M | Buy |
4,292,595
+109,970
| +3% | +$15.1M | 0.09% | 228 |
|
|
2019
Q4 | $550M | Sell |
4,182,625
-688,245
| -14% | -$79.8M | 0.07% | 285 |
|
|
2019
Q3 | $545M | Sell |
4,870,870
-3,745,020
| -43% | -$417M | 0.08% | 260 |
|
|
2019
Q2 | $955M | Sell |
8,615,890
-13,891,867
| -62% | -$1.64B | 0.13% | 168 |
|
|
2019
Q1 | $2.92B | Buy |
22,507,757
+2,772,047
| +14% | +$337M | 0.43% | 47 |
|
|
2018
Q4 | $2.28B | Buy |
19,735,710
+14,205,563
| +257% | +$1.59B | 0.39% | 58 |
|
|
2018
Q3 | $593M | Buy |
5,530,147
+2,800,631
| +103% | +$280M | 0.09% | 237 |
|
|
2018
Q2 | $233M | Sell |
2,729,516
-1,129,043
| -29% | -$92.7M | 0.04% | 433 |
|
|
2018
Q1 | $299M | Sell |
3,858,559
-656,392
| -15% | -$52.8M | 0.05% | 368 |
|
|
2017
Q4 | $381M | Sell |
4,514,951
-55,532
| -1% | -$4.72M | 0.06% | 319 |
|
|
2017
Q3 | $391M | Sell |
4,570,483
-985,380
| -18% | -$80.8M | 0.07% | 306 |
|
|
2017
Q2 | $457M | Sell |
5,555,863
-1,887,786
| -25% | -$154M | 0.08% | 260 |
|
|
2017
Q1 | $626M | Buy |
7,443,649
+459,307
| +7% | +$36.8M | 0.12% | 203 |
|
|
2016
Q4 | $514M | Sell |
6,984,342
-6,131,221
| -47% | -$457M | 0.1% | 230 |
|
|
2016
Q3 | $1.05B | Sell |
13,115,563
-1,786,342
| -12% | -$143M | 0.21% | 112 |
|
|
2016
Q2 | $1.17B | Sell |
14,901,905
-1,324,348
| -8% | -$99.7M | 0.25% | 101 |
|
|
2016
Q1 | $1.17B | Sell |
16,226,253
-2,658,967
| -14% | -$201M | 0.25% | 103 |
|
|
2015
Q4 | $1.59B | Buy |
18,885,220
+106,659
| +0.6% | +$8.85M | 0.33% | 72 |
|
|
2015
Q3 | $1.57B | Sell |
18,778,561
-906,113
| -5% | -$76.5M | 0.35% | 68 |
|
|
2015
Q2 | $1.64B | Sell |
19,684,674
-930,313
| -5% | -$70.9M | 0.34% | 71 |
|
|
2015
Q1 | $1.5B | Sell |
20,614,987
-3,560,911
| -15% | -$254M | 0.31% | 78 |
|
|
2014
Q4 | $1.67B | Buy |
24,175,898
+7,351,235
| +44% | +$496M | 0.35% | 61 |
|
|
2014
Q3 | $1.09B | Buy |
16,824,663
+15,218,256
| +947% | +$964M | 0.24% | 108 |
|
|
2014
Q2 | $99.9M | Buy |
1,606,407
+16,245
| +1% | +$969K | 0.02% | 633 |
|
|
2014
Q1 | $93.6M | Sell |
1,590,162
-1,856,555
| -54% | -$104M | 0.02% | 654 |
|
|
2013
Q4 | $176M | Sell |
3,446,717
-48,960
| -1% | -$2.45M | 0.04% | 462 |
|
|
2013
Q3 | $176M | Sell |
3,495,677
-235,090
| -6% | -$12.3M | 0.04% | 432 |
|
|
2013
Q2 | $183M | Buy |
+3,730,767
| New | +$203M | 0.05% | 411 |
|
Other funds holding LLY
VCM
VPM
T. Rowe Price Associates's LLY Position: Q1 2026 in Review
T. Rowe Price Associates reduced its Eli Lilly (LLY) stake by 6.2% in Q1 2026, selling an estimated $931M and leaving 13,992,224 shares worth $12.9B. The position accounts for 1.49% of the portfolio, ranked #9.
T. Rowe Price Associates first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.7B in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- T. Rowe Price Associates held 13,992,224 shares of Eli Lilly worth $12.9B as of Q1 2026.
- T. Rowe Price Associates sold 918,281 Eli Lilly shares in Q1 2026, an estimated $931M.
- Eli Lilly made up 1.49% of T. Rowe Price Associates's portfolio in Q1 2026, its #9 holding.
- T. Rowe Price Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Eli Lilly position peaked at $18.7B in Q2 2024.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.